A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy

BACKGROUND: H.P. Acthar® Gel is currently the only Food and Drug Administration therapy approved for the treatment of nephrotic syndrome. Active drug ingredients include structurally related melanocortin peptides that bind to cell surface G-protein-coupled receptors known as melanocortin receptors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hladunewich, Michelle A., Cattran, Daniel, Beck, Laurence H., Odutayo, Ayodele, Sethi, Sanjeev, Ayalon, Rivka, Leung, Nelson, Reich, Heather, Fervenza, Fernando C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
CLINICAL SCIENCE
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106642/
https://www.ncbi.nlm.nih.gov/pubmed/24714414
http://dx.doi.org/10.1093/ndt/gfu069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106642/
https://www.ncbi.nlm.nih.gov/pubmed/24714414
http://dx.doi.org/10.1093/ndt/gfu069

Ejemplares similares